SCHEMBL12295267

SCHEMBL12295267

C[C@H](NC(=O)CCCCCCCCCCCCCCC(=O)O)C(=O)O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 5/20 0.63
PLA2G10 O15496 2/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
SLC6A5 Q9Y345 1/20 0.51
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
MAPK1 P28482 1/20 0.50
PLA2G2C Q5R387 1/20 0.49
TSHR P16473 4/20 0.48
LMNA P02545 1/20 0.48
NFKB1 P19838 1/20 0.48
PMP22 Q01453 1/20 0.48
ALDH1A1 P00352 3/20 0.47
MAPT P10636 1/20 0.47
PPARG P37231 4/20 0.45
PPARD Q03181 4/20 0.45
PPARA Q07869 4/20 0.45
GPR84 Q9NQS5 3/20 0.45
HDAC11 Q96DB2 3/20 0.45
TDP1 Q9NUW8 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15850011 1.00 FAAH (0.63) FAAHPLA2G10SMN1; SMN2SLC6A5MEN1
SCHEMBL15680128 1.00 FAAH (0.63) FAAHPLA2G10SMN1; SMN2SLC6A5MEN1
SCHEMBL15680096 1.00 FAAH (0.63) FAAHPLA2G10SMN1; SMN2SLC6A5MEN1
SCHEMBL14331545 1.00 FAAH (0.63) FAAHPLA2G10SMN1; SMN2SLC6A5MEN1
SCHEMBL71908 1.00 FAAH (0.63) FAAHPLA2G10SMN1; SMN2SLC6A5MEN1
SCHEMBL15602821 0.98 FAAH (0.60) FAAHPLA2G10SMN1; SMN2SLC6A5MEN1
SCHEMBL15602822 0.98 FAAH (0.60) FAAHPLA2G10SMN1; SMN2SLC6A5MEN1
SCHEMBL4572557 0.94 FAAH (0.56) FAAHPLA2G10SMN1; SMN2SLC6A5MEN1
SCHEMBL30838580 0.94 FAAH (0.69) FAAHPLA2G10SMN1; SMN2SLC6A5MEN1
SCHEMBL30838579 0.94 FAAH (0.69) FAAHPLA2G10SMN1; SMN2SLC6A5MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210094999-A1 Novel Acylated Insulin Analogues and Uses Thereof NOVO NORDISK AS (DK) 2021-04-01 US disclosed
US-10570184-B2 GLP-1/glucagon receptor co-agonists for medical use NOVO NORDISK A/S (DK) 2020-02-25 US disclosed
US-20170101454-A1 GLP-1/Glucagon Receptor Co-Agonists for Medical Use NOVO NORDISK A/S (DK) 2017-04-13 US disclosed
US-8815802-B2 GLP-1 analogues and derivatives NOVO NORDISK A/S (DK) 2014-08-26 US disclosed
US-8815802-B2 GLP-1 analogues and derivatives NOVO NORDISK A/S (DK) 2014-08-26 US disclosed
US-20130053311-A1 GLP-1 ANALOGUES AND DERIVATIVES NOVO NORDISK A/S (DK) 2013-02-28 US disclosed
US-20130053311-A1 GLP-1 ANALOGUES AND DERIVATIVES NOVO NORDISK A/S (DK) 2013-02-28 US disclosed
WO-2011117415-A1 NOVEL GLUCAGON ANALOGUES NOVO NORDISK A/S (DK) 2011-09-29 WO disclosed
WO-2011117416-A1 NOVEL GLUCAGON ANALOGUES NOVO NORDISK A/S (DK) 2011-09-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170101454-A1 GLP-1/Glucagon Receptor Co-Agonists for Medical Use GLP1R, GCGR, GIPR FAAH 739/4885PLA2G10 1815/4885SMN1; SMN2 3632/4885
US-10570184-B2 GLP-1/glucagon receptor co-agonists for medical use GLP1R, GCGR, GIPR FAAH 755/4885PLA2G10 1816/4885SMN1; SMN2 3640/4885
US-20130053311-A1 GLP-1 ANALOGUES AND DERIVATIVES GLP1R, IAPP, SLC5A1 FAAH 1807/4885PLA2G10 4084/4885SMN1; SMN2 3452/4885
US-20210094999-A1 Novel Acylated Insulin Analogues and Uses Thereof IAPP, GPR119, INSR FAAH 491/4885PLA2G10 1199/4885SMN1; SMN2 2449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.